EMA Releases Guidelines on Advanced Therapies

Article

The new guidelines discuss GMPs and patient protection specific to advanced therapy medicinal products.

On Nov. 24, 2017, the European Medicines Agency (EMA) published good manufacturing practice (GMP) guidelines specific to advanced therapy medicinal products (ATMPs). The guidelines adapt European Union GMPs to ATMPs and address the complex manufacturing issues that are associated with these products. The guidelines promote a risk-based approach to manufacturing and testing ATMPs within high quality standards.

The guidelines are part of a joint action plan launched by the Directorate General for Health and Food Safety (DG SANTE) and EMA in October 2017 to foster the development of ATMPs. They were developed with input from EMA’s Committee for Advanced Therapies and GMP/Good Distribution Practice Inspectors Working Group.

ATMPs are treatments based on gene or cells and can offer new options for patients with severe, untreatable, or chronic conditions.

Source: EMA

Recent Videos
Simon Wright from Almac Pharma Services chats about shifting demand for commercial manufacturing services and how service providers are adapting to meet demand.
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Kate Coleman, vice president regulatory affairs, quality and compliance, Arriello, chats about industry trends and technological advances.
Industry Outlook 2025: The Rising Prominence of AI in Pharma
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Related Content
© 2025 MJH Life Sciences

All rights reserved.